Applied Genetic Technologies (NASDAQ:AGTC)‘s stock had its “hold” rating reaffirmed by Cantor Fitzgerald in a research report issued on Wednesday. They currently have a $9.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 125.00% from the company’s current price.
Other analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Wedbush reiterated an “outperform” rating and set a $9.00 price target on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Zacks Investment Research lowered shares of Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, ValuEngine lowered shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $10.17.
Shares of Applied Genetic Technologies (NASDAQ AGTC) traded up $0.05 during trading hours on Wednesday, hitting $4.00. 36,703 shares of the company’s stock were exchanged, compared to its average volume of 113,103. Applied Genetic Technologies has a 1 year low of $3.25 and a 1 year high of $9.45. The firm has a market cap of $72.37, a price-to-earnings ratio of -15.38 and a beta of 1.61.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nine Chapters Capital Management LLC acquired a new stake in shares of Applied Genetic Technologies during the 3rd quarter worth approximately $113,000. Virtu KCG Holdings LLC acquired a new stake in shares of Applied Genetic Technologies during the 2nd quarter worth approximately $178,000. Citadel Advisors LLC boosted its position in shares of Applied Genetic Technologies by 304.6% during the 3rd quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 31,070 shares in the last quarter. Ativo Capital Management LLC acquired a new stake in Applied Genetic Technologies in the second quarter valued at approximately $439,000. Finally, ClariVest Asset Management LLC boosted its position in Applied Genetic Technologies by 18.5% in the third quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock valued at $391,000 after buying an additional 15,491 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.